Benzinga | Aug 2, 2021 06:17AM EDT

HC Wainwright & Co. Maintains Buy on AzurRx BioPharma, Lowers Price Target to $2

HC Wainwright & Co. analyst Yi Chen maintains AzurRx BioPharma (NASDAQ:AZRX) with a Buy and lowers the price target from $2.5 to $2.